Description
Canagliflozin is an SGLT2 inhibitor.
Canagliflozin
Product ID C017521
Cas No. 842133-18-0
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 842133-18-0 |
|---|---|
| Purity | ≥98% |
| Formula | C24H25FO5S |
| Formula Wt. | 444.52 |
| Synonym | JNJ-24831754 |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Londzin P, Zych M, Janas A, et al. Effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin and canagliflozin, on the musculoskeletal system in an experimental model of diabetes induced by high-fat diet and streptozocin in rats. Biomed Pharmacother. 2025 Mar:184:117912. PMID: 39955854.
Taguchi D, Shirakami Y, Sakai H, et al. Dual roles of canagliflozin on cholangiocarcinoma cell growth and enhanced growth suppression in combination with FK866. Int J Mol Sci. 2025 Jan 24;26(3):978. PMID: 39940750.
Luo J, He M, Liang C, et al. Canagliflozin reverses doxorubicin-induced cardiotoxicity via restoration of autophagic homeostasis. Toxicol Appl Pharmacol. 2025 Feb:495:117183. PMID: 39631538.
Elariny H, Kabel A, Selim H, et al. Repositioning canagliflozin for mitigation of aluminium chloride-induced Alzheimer’s disease: involvement of TXNIP/NLRP3 inflammasome axis, mitochondrial dysfunction, and SIRT1/HMGB1 signalling. Medicina (Kaunas). 2024 Nov 3;60(11):1805. PMID: 39596990.